Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Study on Mri Changes in Phenylketonuria in Patients Referred to Mofid Hospital/Iran



Karimzadeh P1, 2 ; Ahmadabadi F3 ; Jafari N1 ; Shariatmadari F4 ; Nemati H1 ; Ahadi A5 ; Karimi Dardashti S6 ; Mirzarahimi M7 ; Dastborhan Z8 ; Zare Noghabi J9
Authors
Show Affiliations
Authors Affiliations
  1. 1. Pediatric Neurology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  2. 2. Pediatric Neurology Department, Mofid Children Hospiutal, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  3. 3. Pediatric Neurology Department, Ardabil University of Medical Sciences, Ardabil, Iran
  4. 4. Pediatric Neurology Department, Arak University of Medical Sciences, Arak, Iran
  5. 5. Pediatric Department, Ardabil University of Medical Sciences, Ardabil, Iran
  6. 6. Surgery Department, Tehran University of Medical Sciences, Tehran, Iran
  7. 7. Department of Neonatology, Ardabil University of Medical Sciences, Ardabil, Iran
  8. 8. Ophthalmology Department, Isfahan University of Medical sciences, Isfahan, Iran
  9. 9. Pediatric Nephrology Department, Ardabil University of Medical Scinces, Ardabil, Iran

Source: Iranian Journal of Child Neurology Published:2014

Abstract

Objective Phenylketonuria is one of the most common metabolic disorders and the first known cause of mental retardation in pediatrics. As Screening for phenylketonuria (PKU) is not a routine neurometabolic screening test for neonates in Iran, many PKU cases may be diagnosed after developing the clinical symptoms. One of the findings of PKU is myelination disorders, which is seen as hypersignal regions in T2-weighted (T2W) and FLAIR sequences of brain MRI. The aim of our study was to assess MRI changes in PKU patients referred to Mofid Children's Hospital, 2010-2011. Materials & Methods We studied all PKU cases referred to our clinic as a referral neurometabolic center in Iran for brain MRI and assessed the phenylalanine level at the time of Imaging. The mean phenylalanine level (in one year), clinical manifestations, and MRI pattern based on Thompson scoring, were evaluated. Results The mean age of our study group was 155±99 months and the mean diagnosis age was 37±27.85 months. There were 15 patients with positive and 15 with negative family history. The mean phenylalanine level at the time of imaging was 9.75±6.28 and the mean 1 year phenylalanine level was 10.28±4.82. Seventy percent of our patients had MRI involvement, in whom 20% showed atrophic changes, in addition to white matter involvement. Based on modified Thompson scoring, the score for our study group was 4.84. The maximum involvement in MRI was in occipital region, followed by parietal, frontal, and temporal zones. There was not any correlation between MRI score and patients' age. But we found significant relationship between MRI score and the age of regimen cessation. No correlation was seen between phenylalanine level (at the time of Imaging) and MRI score. But there was a relationship between mean 1 year phenylalanine level and MRI score. Conclusion According to the results of this study, brain MRI and white matter involvement can be used for evaluation of long-term control of phenylalanine level in PKU cases.